X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ORCA-010
Therapeutic Area: Oncology Product Name: ORCA-010
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: CMX Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2021
Details:
The independent DSMB unanimously recommended the continuation of the study without modification. From this recommendation, ORCA Therapeutics will initiate administration of the highest scheduled dose level of ORCA-010 in the single dose part of the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): oNKord
Therapeutic Area: Oncology Product Name: oNKord
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
WiNK is a two-stage phase I/IIa trial to study the safety and efficacy of oNKord®, an off-the-shelf, ex. vivo-cultured allogeneic NK cell preparation, AML patients who are in complete morphologic remission with no strong indication for hematopoietic stem cell transplantation.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
